Hear how past DES lessons and today’s newest tech are shaping Medtronic’s future coronary strategy

MedtronicTalks

Content provided by MedtronicTalks and Tom Salemi. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MedtronicTalks and Tom Salemi or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

2y ago 36:53

MP3•Pagina episodului

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on October 10, 2024 22:11 (1M ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

In this episode, Jason Fontana, vice president coronary and renal denervation marketing and strategy at Medtronic, will walk us through Medtronic’s successful entry into the drug-eluting stent market over a decade ago with the Endeavor DES, the first modular drug-eluting stent. With a focus on healing and deliverability, Medtronic overcome a late-start to become a leader of the pack following the approval of the Resolute Integrity DES. We’ll review Medtronic’s current coronary portfolio including Onyx Frontier DES with a dual flex balloon. Fontana will also explain how new technologies and diagnostic techniques will help it set the pace in the coronary space in the future. Thanks to Delve for sponsoring! Thank you for listening to the MedtronicTalks Podcast.

47 episoade

#Tech #MedtronicTalks #Tom Salemi